Cresset Asset Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $48M | Buy |
190,827
+9,241
| +5% | +$1.99M | 0.17% | 92 |
|
|
2026
Q1 | $39.5M | Sell |
181,586
-1,839
| -1% | -$408K | 0.17% | 90 |
|
|
2025
Q4 | $41.9M | Buy |
183,425
+11,304
| +7% | +$2.58M | 0.18% | 88 |
|
|
2025
Q3 | $39.9M | Sell |
172,121
-9,447
| -5% | -$1.92M | 0.17% | 84 |
|
|
2025
Q2 | $33.7M | Sell |
181,568
-27,480
| -13% | -$5.11M | 0.17% | 88 |
|
|
2025
Q1 | $43.8M | Sell |
209,048
-61,558
| -23% | -$12M | 0.22% | 74 |
|
|
2024
Q4 | $48.1M | Sell |
270,606
-72,273
| -21% | -$13.3M | 0.23% | 67 |
|
|
2024
Q3 | $67.7M | Buy |
342,879
+6,385
| +2% | +$1.19M | 0.26% | 55 |
|
|
2024
Q2 | $57.7M | Buy |
336,494
+45,911
| +16% | +$7.61M | 0.24% | 61 |
|
|
2024
Q1 | $52.9M | Buy |
290,583
+79,360
| +38% | +$13.7M | 0.25% | 55 |
|
|
2023
Q4 | $32.7M | Sell |
211,223
-15,907
| -7% | -$2.32M | 0.2% | 74 |
|
|
2023
Q3 | $33.9M | Buy |
227,130
+14,611
| +7% | +$2.14M | 0.13% | 81 |
|
|
2023
Q2 | $28.6M | Buy |
212,519
+157,748
| +288% | +$23.1M | 0.04% | 138 |
|
|
2023
Q1 | $8.73M | Sell |
54,771
-6,238
| -10% | -$954K | 0.17% | 88 |
|
|
2022
Q4 | $7.36M | Buy |
61,009
+4,896
| +9% | +$751K | 0.09% | 94 |
|
|
2022
Q3 | $7.53M | Sell |
56,113
-4,448
| -7% | -$638K | 0.1% | 94 |
|
|
2022
Q2 | $9.06M | Buy |
60,561
+2,420
| +4% | +$370K | 0.11% | 84 |
|
|
2022
Q1 | $9.43M | Sell |
58,141
-23,066
| -28% | -$3.35M | 0.1% | 86 |
|
|
2021
Q4 | $11M | Buy |
81,207
+28,185
| +53% | +$3.33M | 0.11% | 85 |
|
|
2021
Q3 | $5.72M | Buy |
53,022
+8,761
| +20% | +$1M | 0.08% | 102 |
|
|
2021
Q2 | $4.99M | Buy |
44,261
+6,305
| +17% | +$710K | 0.07% | 104 |
|
|
2021
Q1 | $4.11M | Buy |
37,956
+8,622
| +29% | +$922K | 0.07% | 103 |
|
|
2020
Q4 | $3.14M | Sell |
29,334
-3,752
| -11% | -$361K | 0.05% | 116 |
|
|
2020
Q3 | $2.9M | Sell |
33,086
-880
| -3% | -$82.8K | 0.05% | 130 |
|
|
2020
Q2 | $3.33M | Sell |
33,966
-34,773
| -51% | -$3.06M | 0.07% | 106 |
|
|
2020
Q1 | $5.24M | Sell |
68,739
-13,423
| -16% | -$1.14M | 0.16% | 50 |
|
|
2019
Q4 | $7.28M | Sell |
82,162
-23,988
| -23% | -$1.99M | 0.2% | 41 |
|
|
2019
Q3 | $8.04M | Sell |
106,150
-46,898
| -31% | -$3.22M | 0.25% | 47 |
|
|
2019
Q2 | $11.1M | Buy |
153,048
+30,896
| +25% | +$2.43M | 0.35% | 46 |
|
|
2019
Q1 | $2.04M | Buy |
122,152
+108,461
| +792% | +$8.87M | 0.08% | 64 |
|
|
2018
Q4 | $1.26M | Buy |
+13,691
| New | +$1.2M | 0.07% | 59 |
|
Other funds holding ABBV
Cresset Asset Management's ABBV Position: Q2 2026 in Review
Cresset Asset Management increased its AbbVie (ABBV) stake by 5.1% in Q2 2026, buying an estimated $1.99M and bringing the position to 190,827 shares worth $48M. The position accounts for 0.17% of the portfolio, ranked #92.
Cresset Asset Management first reported a position in ABBV in Q4 2018 and has held it in 31 quarters since. The position peaked at $67.7M in Q3 2024. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Cresset Asset Management held 190,827 shares of AbbVie worth $48M as of Q2 2026.
- Cresset Asset Management bought 9,241 AbbVie shares in Q2 2026, an estimated $1.99M.
- AbbVie made up 0.17% of Cresset Asset Management's portfolio in Q2 2026, its #92 holding.
- Cresset Asset Management first reported a position in AbbVie in Q4 2018 and has held it in 31 quarters since.
- Cresset Asset Management's AbbVie position peaked at $67.7M in Q3 2024.
- 4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.